RegWardenFDA facility compliance records
Recall

Class II — Mindray DS USA, Inc. d.b.a. Mindray North America

Recalling firmMindray DS USA, Inc.
Registered facilityMINDRAY DS USA, Inc. (the firm's only registered facility)
ClassificationClass II
StatusTerminated
ReasonThere is a software anomaly with the DPM Central Monitoring System where the trend data of one patient maybe replaced with the trend data of a second patient.
ProductDPM Central Station Mindray DS USA, Inc. 800 MacArthur Boulevard, Mahwah, NJ 07430 The Central Monitoring Station (CMS) network transfers information between DOM Central Station and other network devices. It also allows information transfer between several CMS. Network connections consist of hardwired network cables and or WLAN connections. The DPM Central Station is used for remote monitor management, storing, printing, reviewing, or processing of information from net worked devices, and it is operated by medical personnel in hospitals or medical institutions.
Quantitytwo units
DistributionNationwide Distribution including OH and GA
Initiated2011-05-12
Classified2013-01-03
Terminated2013-02-19
Recall numberZ-0630-2013
InitiationVoluntary: Firm initiated

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this recall record at FDA → (opens in a new tab)

Cite this record

RegWarden. “Class II recall — Mindray DS USA, Inc. d.b.a. Mindray North America (Z-0630-2013).” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/recall/63616/

Not open yet

Alerts for Mindray DS USA, Inc.

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.